Please assess the completion status of the following clinical trial:

Trial Title: Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be a healthy male, at least 21 years old and no more than 60 years old, inclusively. As the effect of the study drug on sperm is still unknown, male subjects will be instructed to refrain from donating sperm or planning a pregnancy during the study and for 90 days after study completion. They will be instructed to tell the study doctor if their partner becomes pregnant during the study or during 90 days after study completion. Male subjects will have to use double-barrier contraceptive methods: male condoms and spermicide.~* Be a healthy, non-pregnant female, at least 21 years old and no more than 60 years old, inclusively, and meet one of the following criteria with regard to child-bearing status:~  1. Be a woman of non-child-bearing potential, defined as surgically sterile (e.g., hysterectomy, tubal ligation) or post-menopausal \[amenorrhea \>1 year and FSH (follicle stimulating hormone) \> 30 microU/ml\] with a negative pregnancy test; OR~ 2. Be a woman of child-bearing potential and practicing a highly effective method of contraception (i.e., \>99% effective when used consistently and correctly, or, in other words, \<1% failure rate per year) including the following methods: Intrauterine Copper Contraceptive (as for example, Paragard T 380A), sexual abstinence, or vasectomized male partner with a negative pregnancy test.~* Have a body mass index (BMI) within the range of \>18.5 and \<32 kg/m2 unless approved by the sponsor and investigator.~* Be a current cannabis smoker of ≥ 1 grams of cannabis per day, at least 6 days per week.~* Meet the diagnostic criteria for Cannabis Use Disorder (CUD) based on DSM-5 criteria~* Have no significant diseases in their medical history or clinically significant findings on physical examination or clinical laboratory evaluations.~* Be informed of the nature of the study and provide signed informed consent.~* Be legally competent and able to communicate effectively with study personnel.~Exclusion Criteria:~* Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems.~* The presence of clinically significant laboratory values. Subjects with AST (aspartate aminotransferase), ALT (alanine transaminase) or GGT (gamma-glutamyltransferase) values \>2x the upper limit of normal, alkaline phosphatase, bilirubin, BUN (blood urea nitrogen), creatinine \>15% above the upper limit of normal, or hemoglobin or hematocrit level \>15% below the lower limit of normal may only be enrolled upon joint agreement of the sponsor and investigator.~* Have abnormal baseline values for the steroid hormones: cortisol, testosterone, estradiol and progesterone in accordance to their reproductive status (for example but not limited to surgical or post-menopausal).~* A history of alcoholism or drug addiction other than cannabis use disorder within the past 2 years, or positive results from a urine screen for substances of abuse other than THC.~* A history of smoking greater than 20 cigarettes per day on average, in the month prior to Screening, or having an inability to abstain from smoking (or use of any nicotine-containing substance) for at least 8 hours.~* A history of major Axis I psychopathology, e.g., mood disorder with functional impairment, schizophrenia).~* Inadequate venous access.~* A known history of Hepatitis B or C or HIV infection.~* Ingestion of an investigational drug or product, or participation in a drug study within a period of 30 days prior to screening (for investigational drugs with an elimination half-life greater than 10 days, this will be extended to 60 days).~* Use of any prescription or over-the-counter (OTC) drug therapy, including herbal, homeopathic, vitamins, minerals and nutritional supplements, unapproved by the sponsor, within 2 weeks prior to receiving the study medication (for drugs with an elimination half-life greater than 10 days, this will be extended to 60 days). The use of any food supplement or body cream containing pregnenolone or any other steroid including phytosteroids.~* Use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days prior to screening or during the study.~* Unable to follow the restrictions outlined in the protocol.~* Previous participation in a cohort for any dose level of AEF0117.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- AEF0117 (Type: EXPERIMENTAL): AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
- Placebo oral capsule (Type: PLACEBO_COMPARATOR): corn oil capsules once a day for 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).